Card image cap
Zydus gets DCGI nod for Desidustat

Indian drugmaker Zydus Lifesciences (formerly Cadila Healthcare ) has received approval for its New Drug Application (NDA) from the Drug Controller General of India (DCGI) for Desidustat (branded as Oxemia), a first-of-its-kind oral treatment in India for anaemia associated with chronic kidney disease (CKD). Oxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment